A phase I study of Human Pharmacokinetics and Safety of ORY-1001, and LSD1 inhibitor, in relapsed or refractory acute leukaemia (AL)

Trial Profile

A phase I study of Human Pharmacokinetics and Safety of ORY-1001, and LSD1 inhibitor, in relapsed or refractory acute leukaemia (AL)

Completed
Phase of Trial: Phase I/II

Latest Information Update: 24 Mar 2017

At a glance

  • Drugs RG 6016 (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics; Proof of concept
  • Sponsors Oryzon
  • Most Recent Events

    • 30 Jan 2017 According to an Oryzon Genomics media release, top line results of this trial will be summarized at the Keystone Symposia on Epigenetics and Human Disease 2017.
    • 25 Jan 2017 Status changed from recruiting to completed, as reported in an Oryzon Genomics media release.
    • 09 Jan 2017 According to an Oryzon Genomics media release, this trial is in the process of final data analysis and closing.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top